BlackRock Health Sciences Trust II (BMEZ)vsJPMorgan Chase & Co (JPM)
BMEZ
BlackRock Health Sciences Trust II
$14.33
-0.97%
FINANCIAL SERVICES · Cap: $904.39M
JPM
JPMorgan Chase & Co
$312.37
+2.31%
FINANCIAL SERVICES · Cap: $806.43B
Smart Verdict
WallStSmart Research — data-driven comparison
JPM leads profitability with a 33.9% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.7x. JPM earns a higher WallStSmart Score of 73/100 (B).
BMEZ
Avoid30
out of 100
Grade: F
JPM
Strong Buy73
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 43.7%
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 5.7% — below average capital efficiency
Expensive relative to growth rate
Negative free cash flow — burning cash
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BMEZ
The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.
Bull Case : JPM
The strongest argument for JPM centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 33.9% and operating margin at 43.7%. Revenue growth of 12.7% demonstrates continued momentum.
Bear Case : BMEZ
The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.
Bear Case : JPM
The primary concerns for JPM are PEG Ratio, Free Cash Flow, Altman Z-Score. Debt-to-equity of 3.39 is elevated, increasing financial risk.
Key Dynamics to Monitor
BMEZ profiles as a value stock while JPM is a mature play — different risk/reward profiles.
JPM is growing revenue faster at 12.7% — sustainability is the question.
BMEZ generates stronger free cash flow (79M), providing more financial flexibility.
Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JPM scores higher overall (73/100 vs 30/100), backed by strong 33.9% margins and 12.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BlackRock Health Sciences Trust II
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund designed to deliver high total returns by investing in a diversified portfolio focused primarily on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by BlackRock's extensive investment management experience, BMEZ seeks to capitalize on substantial growth prospects driven by demographic shifts and increasing healthcare spending. The fund's disciplined and strategic investment approach positions it as a compelling choice for institutional investors looking to enhance their portfolios while navigating the dynamic and innovative landscape of the health sciences industry.
JPMorgan Chase & Co
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
JPMorgan Chase & Co. is an American multinational investment bank and financial services holding company headquartered in New York City. JPMorgan Chase is incorporated in Delaware. As a Bulge Bracket bank, it is a major provider of various investment banking and financial services. It is one of America's Big Four banks, along with Bank of America, Citigroup, and Wells Fargo. JPMorgan Chase is considered to be a universal bank and a custodian bank. The J.P. Morgan brand is used by the investment banking, asset management, private banking, private wealth management, and treasury services divisions.
Visit Website →Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?